OCEANIC-STROKE / Asundexian
For 20 years, stroke prevention has carried a built-in tax: every drug that prevents clots has also raised bleeding risk. OCEANIC-STROKE may be the first Phase III trial to credibly break that trade-off.
The data
▪ 12,327 patients with non-cardioembolic ischemic stroke or high-risk TIA, on top of antiplatelet therapy.
▪ Recurrent ischemic stroke: 6.2% vs. 8.4% — a 26% relative reduction (csHR 0.74; 95% CI 0.65–0.84; P<0.001). Absolute risk reduction 2.2 percentage points; NNT ≈ 46.
▪ ISTH major bleeding: 1.9% vs. 1.7% — no significant increase (p=0.46).
▪ NEJM, April 2026 (Sharma et al.); sub-analyses headlined ESOC 2026 in Maastricht.
The mechanism is the news
Factor XIa drives pathological clot formation while playing only a minimal role in the initiation of normal hemostasis. (Congenital FXI deficiency does cause mild bleeding — typically with surgery or major trauma — but not the spontaneous bleeds that limit current DOACs.) If the safety signal holds in real-world use, the field finally has a way to prevent stroke without the bleeding tax.
The more interesting question is upstream: even with flat average bleeding rates, some patients will bleed. Identifying them in advance — through systematic quantification of microbleeds, cortical superficial siderosis, white matter burden, and CAA markers on baseline MRI — is a real unmet need.
That points toward a precision-anticoagulation decision-support category — distinct from acute triage AI. The hypothesis is plausible; the market is not yet validated.
#StrokeAI #Neurology #Neuroradiology #ImagingIT #ComprehensiveStrokeCenter